Abstract 21P
Background
Clinical trial registries record the proposed and actual completion date of studies. Study duration affects budget, personnel, governance and ethics. To our knowledge, no data exists comparing estimated time to study completion with actual completion date. Using breast cancer trials as an exemplar, we analyzed differences between estimated and actual duration of clinical trials.
Methods
A sophisticated artificial intelligence (AI) tool, Risklick AI®1-3 analysed clinical trial registry fields for proposed trial completion (entered at time of study registration) compared to date entered for study completion. This technology collects and unifies trial data from all 18 public registries, including clinicaltrials.gov and WHO. The comprehensive search performed on 15.3.23 for period 2000 – 2023 used 101 keywords to cover breast cancer subtypes in completed trials. Trials were analyzed according to factors postulated to impact duration: disease extent, histological subtype, phase, number of eligibility criteria, sample size, country and sponsor. Delay was defined as the additional time required to complete the trial compared to the estimated study completion date, with a tolerance of 30 days.
Results
582 trials, involving 104’384 patients, recorded both planned and actual completion dates. Overall, 21.6% were finished early, 7.9% on time, and 70.4% had delay, of mean 31.7 +/- 25.6 months [standard deviation], ranging 1 - 155 months. The mean delay was similar for trials analysed by disease extent, breast cancer subtype, phase, number of eligibility criteria, sample size, country, or sponsor type.
Conclusions
This large real-world dataset revealed an average delay in completion of 2.5-year for 70% of breast cancer trials, independent of multiple factors commonly thought to affect trial duration. This data should be considered when planning, budgeting and setting participant and community expectations for trials. Tools to accurately predict trial duration and efforts to reduce delays are needed.
References: 1. www.risklick.ch 2. Front Digit Health. 2021;3 3. Pharmacology. 2021;106(5-6):244-253.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Bern.
Funding
Has not received any funding.
Disclosure
P. Khlebnikov, F. Meer, Q. Haas: Financial Interests, Personal, Full or part-time Employment: Risklick AG. P. Amini: Financial Interests, Personal, Ownership Interest: Risklick AG. E. Segelov: Financial Interests, Personal, Invited Speaker, Limbic are a medical educational company running various seminars which I have participated in as an invited speaker/Chair: Limbic; Financial Interests, Personal, Invited Speaker, webinar on colorectal cancer 28/02/21: Servier; Financial Interests, Institutional, Local PI, As head of the Oncology Cancer clinical trials at Monash Health (until 15 Aug 2022) where there were >200 trials active, there were the usual commercial arrangements to run the trials with the institution. There was no personal financial benefit from any: > 15 different companies. All other authors have declared no conflicts of interest.
Resources from the same session
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract